Boeing vs. Lockheed Martin: Which Essential U.S. Aerospace Stock Is a Better Buy in 2026?

Lockheed Martin is presented as the preferable long-term value investment, trading at 17.3x forward P/E and 1.6x sales versus Boeing at 49.7x and 1.7x, respectively. Boeing's FY2025 revenue rose 35% to $89.5B and net income recovered to $2.2B, but it had negative $1.9B free cash flow, 10.0x debt-to-equity, and faces FAA, production, certification, and supply-chain risks. Lockheed generated $75.1B of FY2025 revenue (+6%), more than $5B of net income, and $6.9B of free cash flow, supported by long-duration defense contracts and an F-35 program contributing about 27% of sales.

Analysis

The relevant spread is not commercial aerospace demand versus defense stability; it is cash conversion versus embedded execution optionality. BA's equity remains a residual claim on certification progress, supplier stabilization, and working-capital release, so incremental delivery-rate gains can create outsized FCF upside over 6-18 months—but only after cash interest, remediation costs, and production inefficiencies are absorbed. AIR is the cleaner second-order beneficiary if Boeing's operating constraints persist: airline capacity growth and replacement demand can migrate to Airbus without Airbus assuming Boeing's balance-sheet or FAA-risk discount.

LMT offers a materially more defensible earnings base, but the market should not treat its backlog as synonymous with unconstrained margin growth. Fixed-price development exposure, munitions/propulsion supply bottlenecks, and a continuing-resolution or defense-budget delay can defer margin and cash conversion over the next 1-3 months even when demand is intact. Within defense, RTX and GD provide more diversified exposure to missile replenishment, air defense, aftermarket, and naval programs; this diversification becomes valuable if the F-35 procurement cadence or export approvals disappoint.

Consensus likely overstates the binary distinction: BA does not need a pristine turnaround for equity upside, only enough delivery normalization to shift the valuation debate from survival liquidity to FCF yield. Conversely, LMT's apparent earnings discount may be appropriate if program mix and government contracting scrutiny prevent margin expansion. The near-term catalyst set favors LMT on budget visibility and capital returns, while BA needs independently verifiable monthly delivery/production evidence rather than backlog headlines; a renewed FAA restriction, supplier disruption, or negative FCF guidance revision would quickly re-rate BA lower.

Key Decisions for Investors

• Initiate a 6-12 month long LMT / short BA pair, sized beta-neutral. This expresses superior cash-flow quality and limits broad aerospace-demand risk; target a 10-15% relative return, with a stop if BA demonstrates two consecutive quarters of positive FCF plus credible production-rate expansion or if LMT cuts full-year cash-flow guidance.
• Use AIR as the preferred long-duration commercial aerospace exposure rather than outright BA for the next 6-18 months. Accumulate on industry-wide delivery or tariff-driven pullbacks; thesis fails if Airbus delivery guidance is reduced because its own supply chain cannot convert backlog into aircraft.
• Maintain a tactical BA watch rather than a core long until monthly deliveries, 737 production authorization, supplier quality metrics, and management's FCF bridge support a durable positive-FCF inflection. If those data improve, buy 9-15 month BA call spreads rather than common stock to capture turnaround convexity while capping certification-tail risk.
• For defense exposure, diversify LMT with RTX rather than adding NOC or GD solely on a defense-spending thesis. RTX offers greater aftermarket and air-defense sensitivity; reassess if a U.S. appropriations delay extends beyond one quarter or missile/engine supply constraints force a cash-flow guide-down.